Risk of hospitalisation and mortality among patients with interstitial lung disease and COVID-19: A French multicentre prospective cohort

Rémi Diesler; Laure Gallay; Y. Uzunhan; Raphaël Borie; M. Reynaud-Gaubert; V. Valentin; Kaïs Ahmad; Romain Lazor; L Wemeau; Julie Traclet; Pierre Rigaud; S. Marchand‐Adam; Sandrine Hirschi; Philippe Bonniaud; David Montani; Jean‐Marc Naccache; Nicolas Romain‐Scelle; Vincent Cottin

doi:10.1080/25310429.2025.2598693

Key Points

Assess hospitalisation and mortality risks among patients with interstitial lung disease (ILD) and COVID-19.
Multicentre prospective cohort study
Included patients with ILD diagnosed with COVID-19
Analyzed outcomes based on ILD subtype and treatment history
Higher mortality associated with certain ILD subtypes
Background glucocorticoid therapy increased risk of severe outcomes
Vaccination status correlated with improved patient outcomes

Implication

Cohort study finds serious outcomes from COVID-19 in patients with interstitial lung disease, suggesting vaccination and therapy influence results.

Abstract

Poor outcomes related to COVID-19 are associated with ILD subtype and severity, background glucocorticoid therapy and absence of vaccination. There is no evidence of late mortality.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Diesler et al. (2025) studied this question.

synapsesocial.com/papers/69401d622d562116f28f8d73 https://doi.org/10.1080/25310429.2025.2598693

View Full Paper

Ask AI

Bookmark

Share

Risk of hospitalisation and mortality among patients with interstitial lung disease and COVID-19: A French multicentre prospective cohort

Key Points

Implication

Abstract

Discussion

Cite This Study

Risk of hospitalisation and mortality among patients with interstitial lung disease and COVID-19: A French multicentre prospective cohort

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading